Methylphenobarbital
From Wikipedia, the free encyclopedia
 |
|
|
Methylphenobarbital
|
|
| Systematic (IUPAC) name | |
| 5-phenyl-5-ethyl- 3-methylbarbituric acid |
|
| Identifiers | |
| CAS number | |
| ATC code | N03 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C13H14N2O3 |
| Mol. mass | 246.3 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 70-76% |
| Metabolism | Hepatic |
| Half life | 34 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Methylphenobarbital, also known as mephobarbital, (marketed in the US under the brand name Mebaral by Ovation) is a drug which is a barbiturate derivative.
Methylphenobarbital is used as a sedative, anxiolytic and anticonvulsant. It is the N-methylated analogue of phenobarbital, and has similar indications, therapeutic value, and tolerability.
[edit] Approval History
- 1935 Mebaral was introduced by Winthrop Pharmaceuticals.
- 2001 Methylphenobarbital discontinued in the UK.
- 2003 Mebaral acquired by Ovation Pharmaceuticals (specialty pharmaceutical company who acquire underpromoted branded pharmaceutical products).
[edit] Overdose symptoms
Symptoms of overdose of metharbital include confusion, decrease in or loss of reflexes, somnolence, pyrexia, irritability, hypothermia, poor judgment, shortness of breath or slow/troubled breathing, slow heartbeat, slurred speech, staggering, trouble in sleeping, unusual movements of the eyes, weakness
[edit] References
- The Treatment of Epilepsy 2nd Ed by S. D. Shorvon (Editor), David R. Fish (Editor), Emilio Perucca (Editor), W. Edwin Dodson (Editor). Published by Blackwell 2004. ISBN 0-632-06046-8
|
|||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
